GlassScriptPhysician profile
Kelechi Weze
NPI 1275030132
$44,746.59
in general payments reported to CMS, 2019-2025
8 companies · $38K in 2025
The $38K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $117 · 2024: $6,861 · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $39K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,067 · Food and Beverage: $2,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $39,392.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,066.78 |
| Food and Beverage | $2,170.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $37,686.09 | 2024-2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $5,372.25 | 2024-2025 | General - Structural Heart, Rotapro, General - Vascular Access |
| Shockwave Medical, INC | $1,057.14 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $288.32 | 2025 | Pascal, Sapien 3 Ultra Resilia |
| Abiomed | $150.58 | 2024 | Impella |
| Novo Nordisk INC | $117.15 | 2022 | |
| Chiesi USA, INC. | $48.73 | 2024-2025 | Kengreal |
| Pfizer INC. | $26.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelechi Weze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.